Exelixis Inc
NASDAQ:EXEL
Intrinsic Value
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. [ Read More ]
The intrinsic value of one EXEL stock under the Base Case scenario is 22.82 USD. Compared to the current market price of 23.73 USD, Exelixis Inc is Overvalued by 4%.
Valuation Backtest
Exelixis Inc
Run backtest to discover the historical profit from buying and selling EXEL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Exelixis Q4 Revenues Rise; Share Buybacks Continue
2023-Q4 Earnings Call
Exelixis disclosed a total revenue of $480 million in Q4 2023, with cabozantinib franchise accounting for $429 million. Operating expenses dropped to $398 million from Q3's $490 million due to reduced R&D licensing costs. The company reported a GAAP net income of $85.5 million and a non-GAAP net income of $104.2 million. Completion of a $550 million share repurchase program from March 2023 and an ongoing $450 million program collectively aim to return $1 billion to shareholders by 2024 end. Forecasting a 30% gross to net for 2024, they maintain strong cash reserves of $1.7 billion for internal R&D and business development.
Balance Sheet Decomposition
Exelixis Inc
Current Assets | 1.3B |
Cash & Short-Term Investments | 995.3m |
Receivables | 237.4m |
Other Current Assets | 85.2m |
Non-Current Assets | 1.6B |
Long-Term Investments | 728.7m |
PP&E | 128.7m |
Intangibles | 63.7m |
Other Non-Current Assets | 703.3m |
Current Liabilities | 394.3m |
Accounts Payable | 33.8m |
Accrued Liabilities | 192.5m |
Other Current Liabilities | 168m |
Non-Current Liabilities | 284.2m |
Other Non-Current Liabilities | 284.2m |
Earnings Waterfall
Exelixis Inc
Revenue
|
1.8B
USD
|
Cost of Revenue
|
-72.5m
USD
|
Gross Profit
|
1.8B
USD
|
Operating Expenses
|
-1.6B
USD
|
Operating Income
|
170.9m
USD
|
Other Expenses
|
36.9m
USD
|
Net Income
|
207.8m
USD
|
Free Cash Flow Analysis
Exelixis Inc
What is Free Cash Flow?
EXEL Profitability Score
Profitability Due Diligence
Exelixis Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Exelixis Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
EXEL Solvency Score
Solvency Due Diligence
Exelixis Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Exelixis Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXEL Price Targets Summary
Exelixis Inc
According to Wall Street analysts, the average 1-year price target for EXEL is 27.27 USD with a low forecast of 18.18 USD and a high forecast of 33.6 USD.
Ownership
EXEL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EXEL Price
Exelixis Inc
Average Annual Return | -7.79% |
Standard Deviation of Annual Returns | 17.85% |
Max Drawdown | -45% |
Market Capitalization | 7.2B USD |
Shares Outstanding | 303 193 984 |
Percentage of Shares Shorted | 3.36% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. The company is headquartered in Alameda, California and currently employs 954 full-time employees. The company went IPO on 2000-04-11. The firm is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Contact
IPO
Employees
Officers
The intrinsic value of one EXEL stock under the Base Case scenario is 22.82 USD.
Compared to the current market price of 23.73 USD, Exelixis Inc is Overvalued by 4%.